Current Position

Senior Scientist/Department Head, Biostatistics Department
Associate Professor, CING Postgraduate School
The Cyprus Institute of Neurology and Genetics

Education

PhD, Genetic Epidemiology, 2015, University of Cambridge, UK
MSc, Applied Statistics, 2009, University of Oxford, UK
BA, Mathematics, 2008, Aristotle University of Thessaloniki, Greece

Research Interests

• Statistical Genetics and Genetic Epidemiology
• Genetic susceptibility to breast cancer
• Fine mapping 
• Polygenic risk scores
• Classification of Variants of Uncertain clinical Significance (VUS)

Consortia:
Breast Cancer Association Consortium (BCAC), http://bcac.ccge.medschl.cam.ac.uk/
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), http://cimba.ccge.medschl.cam.ac.uk/
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA), https://enigmaconsortium.org/

Biography

Kyriaki Michailidou is an Associate Professor and Head of the Biostatistics Unit at the Cyprus Institute of Neurology and Genetics and a visiting researcher at the Centre for Cancer Genetic Epidemiology at the University of Cambridge.
She is a lead member of the Breast Cancer Association Consortium (BCAC) and the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) and has driven significant advancements in understanding genetic predisposition to different cancers.
Her contributions include the discovery of the majority of breast cancer susceptibility variants, fine-mapping of risk regions, and the development of cutting-edge Polygenic Risk Scores for personalized risk assessment.
These efforts have directly influenced clinical risk prediction models and the classification of Variants of Uncertain Significance (VUS) in high-risk cancer genes, affecting cancer research and practice worldwide. 
Her current research lies in the field of Polygenic Risk Scores, Variant Classification and biomarker discovery.

Selected Publications:

• Mavaddat N., Michailidou K., et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. AJHG, 104(1):21-34, Jan 2019
• Michailidou K., Lindstrom S., Dennis J., et al. Association analysis identifies 65 new breast cancer risk loci. Nature, 551(7678):92–94, Nov 2017. 
• Milne R.L, Kuchenbaecker K.B, Michailidou K. et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat. Genet., 49(12):1767–1778, Dec 2017. 
• Couch F, Kuchenbaecker K.B, Michailidou K. et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun, 7:11375, Apr 2016. 
• Michailidou K., Beesley J., Lindstrom S., et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat. Genet., 47(4):373–380, Apr 2015.
• Michailidou K., Hall P., et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet., 45(4):353–361, Apr 2013.